Episode 81. Current COVID Risk Assessment: BA.2.86 Variant, Boosters, and More
Sep 12, 2023
auto_awesome
Dr. Roger Seheult examines the COVID risk assessment, including the BA.2.86 Variant, boosters, hospitalizations, and T cell immunity. He also discusses a study on myocarditis in COVID-19 recovered patients and factors to consider for booster shots.
The BA 2.86 variant of SARS-CoV-2 may not be as significant a threat as initially thought, as other variants are responsible for the majority of infections and hospitalizations.
Updated booster shots, like the Moderna booster, can significantly increase neutralizing antibody levels against circulating variants, but risks such as myocarditis should be discussed with healthcare providers.
Deep dives
Prevalence of the virus and hospitalizations
The prevalence of COVID-19 is increasing nationwide based on wastewater detection, indicating a steady rise in the disease. Hospitalizations have also increased proportionally in both the United States and Canada, suggesting that the benefits of vaccination and previous infection may be wearing off.
BA 2.86 variant and risk assessment
The BA 2.86 variant of SARS-CoV-2 is notable for having multiple genetic differences from previous versions, raising concerns about immune escape and potentially causing reinfection and reduced vaccine efficacy. However, available data suggests that BA 2.86 may not be as significant a threat as initially thought, as other variants, like EG5 and XBB, are responsible for the majority of infections and hospitalizations.
Efficacy of COVID-19 boosters
Clinical trial data shows that updated booster shots, such as the Moderna booster, can significantly increase neutralizing antibody levels against circulating variants, including BA 2.86. The boosters have demonstrated 8.7 to 11 fold increases in neutralizing antibodies. However, there are still risks to consider, such as myocarditis, especially in males under 40 years of age. People should discuss with their healthcare providers to make informed decisions regarding booster shots.
Roger Seheult, MD of MedCram examines the current COVID risk assessment, including the BA.2.86 Variant, upcoming vaccines boosters, and more. See all Dr. Seheult's videos at: https://www.medcram.com/
He is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine.
MEDCRAM WORKS WITH MEDICAL PROGRAMS AND HOSPITALS:
MedCram offers group discounts for students and medical programs, hospitals, and other institutions. Contact us at customers@medcram.com if you are interested.